JP2022534962A5 - - Google Patents

Info

Publication number
JP2022534962A5
JP2022534962A5 JP2021570724A JP2021570724A JP2022534962A5 JP 2022534962 A5 JP2022534962 A5 JP 2022534962A5 JP 2021570724 A JP2021570724 A JP 2021570724A JP 2021570724 A JP2021570724 A JP 2021570724A JP 2022534962 A5 JP2022534962 A5 JP 2022534962A5
Authority
JP
Japan
Prior art keywords
cells
population
human
nucleic acid
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021570724A
Other languages
English (en)
Japanese (ja)
Other versions
JP7631234B2 (ja
JP2022534962A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035579 external-priority patent/WO2020243713A2/en
Publication of JP2022534962A publication Critical patent/JP2022534962A/ja
Publication of JP2022534962A5 publication Critical patent/JP2022534962A5/ja
Application granted granted Critical
Publication of JP7631234B2 publication Critical patent/JP7631234B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021570724A 2019-05-31 2020-06-01 Cd33陽性悪性腫瘍治療用cd33標的化キメラ抗原受容体修飾t細胞 Active JP7631234B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855906P 2019-05-31 2019-05-31
US62/855,906 2019-05-31
PCT/US2020/035579 WO2020243713A2 (en) 2019-05-31 2020-06-01 Cd33 targeted chimeric antigen receptor modified t cells for treatment of cd33 positive malignancies

Publications (3)

Publication Number Publication Date
JP2022534962A JP2022534962A (ja) 2022-08-04
JP2022534962A5 true JP2022534962A5 (cg-RX-API-DMAC7.html) 2023-06-09
JP7631234B2 JP7631234B2 (ja) 2025-02-18

Family

ID=71842756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021570724A Active JP7631234B2 (ja) 2019-05-31 2020-06-01 Cd33陽性悪性腫瘍治療用cd33標的化キメラ抗原受容体修飾t細胞

Country Status (6)

Country Link
US (1) US12565658B2 (cg-RX-API-DMAC7.html)
EP (1) EP3976794A2 (cg-RX-API-DMAC7.html)
JP (1) JP7631234B2 (cg-RX-API-DMAC7.html)
CN (1) CN114040978B (cg-RX-API-DMAC7.html)
CA (1) CA3142159A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020243713A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2765710T3 (es) * 2014-04-03 2020-06-10 Cellectis Receptores de antígeno quimérico específicos de CD33 para la inmunoterapia del cáncer
CN105384823A (zh) * 2014-08-26 2016-03-09 中国人民解放军总医院 嵌合抗原受体及其基因和重组表达载体、工程化cd33靶向性的nkt细胞及其应用
CN104877032B (zh) * 2015-06-26 2018-12-11 中国医学科学院血液病医院(血液学研究所) Cd33特异性嵌合抗原受体及其应用
HK1256130A1 (zh) 2015-07-21 2019-09-13 City Of Hope 用於嵌合抗原受体和其他受体的表达的t细胞
JP7461620B2 (ja) 2015-10-06 2024-04-04 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 治療用化合物及び方法
MX2019004681A (es) 2016-10-21 2019-10-07 Altor Bioscience Corp Moleculas basadas en il-15 multimericas.
AU2018269194B2 (en) 2017-05-15 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses
CN107267619A (zh) * 2017-07-04 2017-10-20 武汉波睿达生物科技有限公司 一种检测靶向cd33的cart细胞中car表达的荧光定量试剂盒
CN107353343A (zh) * 2017-07-04 2017-11-17 武汉波睿达生物科技有限公司 一种靶向表达cd33表面抗原的细胞的嵌合抗原受体
US20210017277A1 (en) 2018-03-14 2021-01-21 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Anti-cd33 chimeric antigen receptors and their uses

Similar Documents

Publication Publication Date Title
Ghasemi et al. Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy
Hadiloo et al. CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy
ES2602145T3 (es) Inmunoterapia con linfocitos específicos de antígeno seleccionados in vitro después de quimioterapia supresora de linfocitos no mieloablativa
ES3036762T3 (en) A modulatable switch for selection of donor modified cells
ES2589678T3 (es) Uso de linfocitos T de memoria central anti-terceros para el tratamiento anti-leucemia/linfoma
AU2025259838A1 (en) Population of cd3-negative cells that express chemokine receptor and cell adhesion molecule, use of the same, and method for producing the same
Zhong et al. Immunotherapy for hepatocellular carcinoma: current limits and prospects
Wei et al. Effects of tumor irradiation on host T regulatory cells and systemic immunity in the context of adoptive T cell therapy in mice
CN102271702A (zh) 抗第三方中枢记忆性t细胞、产生其的方法及其在移植和疾病治疗中的用途
Parsonidis et al. Adoptive cellular transfer immunotherapies for cancer
Matte-Martone et al. Differential requirements for myeloid leukemia IFN-γ conditioning determine graft-versus-leukemia resistance and sensitivity
Cheng et al. CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma
ES2369077T3 (es) Nuevo procedimiento y composición para producir una vacuna alogénica celular.
Chen et al. Hypofractionated irradiation suppressed the off-target mouse hepatocarcinoma growth by inhibiting myeloid-derived suppressor cell-mediated immune suppression
Ciantra et al. The rewired immune microenvironment in leukemia
Tang et al. miR-aculous new avenues for cancer immunotherapy
ES2869624T3 (es) Inmunoterapia para el tratamiento de cáncer
Grisendi et al. Tumor stroma manipulation by MSC
Chen et al. Nanomedicine strategies for ameliorating cancer by targeting immunosenescence: From challenge to opportunity
Cui et al. Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation
CA2942214C (en) Combination therapy with double negative t-cells
Locatelli et al. Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation
Kloss et al. 638. TGFBeta signaling blockade within PSMA targeted CAR human T cells for the eradication of metastatic prostate Cancer
Rook et al. Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma
US12121554B2 (en) Materials and methods for treatment with oncolytic viruses and modified CAR T cells